InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $2.880 0.7 (32.11%)+
Announcement
Release
19 Feb 2026 8:10AM
Price at Release
$2.180
Full Release
download
Summary
Cogstate Limited has reported strong financial results for the first half of FY2026, with a 12% increase in revenue compared to the previous corresponding period (pcp), reaching $26.9 million. The company has seen significant growth in its clinical trials segment, which now includes 133 ongoing trials, marking a 34% increase year-on-year. Cogstate's strategic investments in AI-powered monitoring and platform modernization have progressed significantly, enhancing their data quality and integration capabilities. Additionally, the company has expanded its portfolio to include mood, sleep, and other neurological disorders, with new trial starts increasing by 68% compared to the pcp. Cogstate has also achieved a record $104.9 million in contracted future revenue, providing strong earnings visibility. The company maintains a robust cash position with $34.1 million and no debt, supporting ongoing growth and strategic investments.
Key Points
  • $26.9 million revenue in 1H26, up 12% vs pcp.
  • 133 ongoing trials, up 34% year-on-year.
  • AI-powered monitoring and platform modernization 75% complete.
  • 42 new trial starts in 1H26, up 68% compared to pcp.
  • $104.9 million in contracted future revenue.
  • Strong cash position with $34.1 million and no debt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.